• 咨询热线
    客服服务热线 13671568941/15317326293
  • 在线咨询
  • 微信客服
    微信客服
  • 公众号
    扫码关注公众号

DS-3032b

CAS No. 1398568-47-2

DS-3032b ( DS 3032b | DS3032b | Milademetan | DS 3032 )

产品货号. M11665 CAS No. 1398568-47-2

DS-3032b 是一种有效的、选择性的、口服的 MDM2-p53 抑制剂,具有潜在的抗肿瘤活性。

纯度: >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
规格 价格/人民币 库存 数量
5MG ¥1397 有现货
10MG ¥2233 有现货
25MG ¥4148 有现货
50MG ¥5831 有现货
100MG ¥7614 有现货
500MG 获取报价 有现货
1G 获取报价 有现货
1 mL x 10 mM in DMSO ¥1862 有现货

生物学信息

  • 产品名称
    DS-3032b
  • 注意事项
    本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
  • 产品简述
    DS-3032b 是一种有效的、选择性的、口服的 MDM2-p53 抑制剂,具有潜在的抗肿瘤活性。
  • 产品描述
    DS-3032b is a potent, selective, orally available MDM2-p53 inhibitor with potential antineoplastic activity; binds to, and prevents the binding of MDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53; restores p53 signaling and leads to the p53-mediated induction of tumor cell apoptosis.Blood Cancer Phase 1 Clinical.
  • 体外实验
    Milademetan (DS-3032) can stabilize TP53 and selectively induce CDKNA1, BAX and MDM2 expression in neuroblastoma cells with wild-type TP53.Milademetan (DS-3032b) treatment enhances TP53 target gene expression and induces G1 cell cycle arrest, senescence and apoptosis.Milademetan (DS-3032b, 0-2000 nM) treatment selectively inhibits viability, proliferation and migration of neuroblastoma cells with wildtype TP53 independently of MYCN status. Cell Viability Assay Cell Line:SK-N-SH, SH-SY5Y, IMR32, IMR5 and LAN5 cell lines.Concentration:0-2000 nM.Incubation Time:24-72 h.Result:Reduced viability in a dose- and time-dependent manner.Exhibited IC50 values of 21.9 nM, 17.7 nM, 52.63 nM, 25.7 nM and 44.1 nM in SK-N-SH, SH-SY5Y, IMR32, IMR5 and LAN5 cell lines, respectively (72 h).
  • 体内实验
    Milademetan (DS-3032b, 50 mg/kg, oral gavage) delays tumor growth and improves survival in mice xenografted with neuroblastoma cells with functional TP53. Animal Model:SH-SY5Y xenograft tumors in nude mice.Dosage:50mg/kg. Administration:Oral gavage for 30 consecutive days with an alternating schedule of 4 days of daily treatment with oral gavages followed by 2 days without treatment (4+2).Result:Survival in the mouse cohort was significantly prolonged.Reduced neuroblastoma xenograft tumor growth by activating TP53 signaling.
  • 同义词
    DS 3032b | DS3032b | Milademetan | DS 3032
  • 通路
    Apoptosis
  • 靶点
    MDM2-p53
  • 受体
    MDM2-p53
  • 研究领域
    Cancer
  • 适应症
    Blood cancer

化学信息

  • CAS Number
    1398568-47-2
  • 分子量
    618.531
  • 分子式
    C30H34Cl2FN5O4
  • 纯度
    >98% (HPLC)
  • 溶解度
    In Vitro:?DMSO : 16.67 mg/mL (26.95 mM)
  • SMILES
    CC1(CCC2(CC1)C3(C(C(N2)C(=O)NC4CCC(OC4)C(=O)N)C5=C(C(=NC=C5)Cl)F)C6=C(C=C(C=C6)Cl)NC3=O)C
  • 化学全称
    (3'R,4'S,5'R)-N-((3S,6R)-6-carbamoyltetrahydro-2H-pyran-3-yl)-6''-chloro-4'-(2-chloro-3-fluoropyridin-4-yl)-4,4-dimethyl-2''-oxodispiro[cyclohexane-1,2'-pyrrolidine-3',3''-indoline]-5'-carboxamide

运输与储存

  • 储存条件
    (-20℃)
  • 运输条件
    With Ice Pack
  • 稳定性
    ≥ 2 years

参考文献

1.?Ishizawa J, et al. Cancer Res. 2018 May 15;78(10):2721-2731.
产品手册
关联产品
  • PK-7088

    PK-7088 是一种小分子突变体 p53 Y220C 重激活剂。

  • PhiKan-083

    p53 突变体 Y220C 的小分子稳定剂,Kd 为 150 uM。

  • DIMP53-1

    一种新型小分子双重抑制剂,通过潜在地与 p53 结合来抑制 p53-MDM2/X 相互作用。